Our Team

At Shortwave Life Sciences, we’re driven by a focused and experienced leadership team with a wealth of knowledge in drug development, clinical research and strategy, particularly within the psychedelic field.

Board of Directors

Rivki Stern Youdkevich

Co-Founder and CEO

Rivki is a Certified Public Accountant (Isr.) with a broad range of finance, strategy and business development expertise, helping to scale IP-driven start-ups in the field of life sciences. Rivki’s international experience in Asia and North America includes raising of over USD 30M for life sciences and biotech companies in the fields of diagnostics, microbiome and aesthetics, and leading go-public campaigns (NASDAQ: IMCC, CSE:IMCC). Rivki served as member of the board at several life-sciences companies and academic institutions, and as consultant to the Israeli government, accelerator programmes and investment funds,

Stephen Murphy

Co-Founder & Executive director

Co-founder of Psych Capital Plc.He founded PSYCH in early 2019 to provide data and intelligence on the emerging psychedelics industry. He is also CEO and co-founder of Prohibition Holdings which owns some of the cannabis industry’s best-known B2B companies and brands including Prohibition Partners, Business of Cannabis, Cannabis Europa and Atalis.

Stephen’s background is in technology, digital media and corporate finance, including roles with Sony Pictures, Unilever and Diageo.

Roy Kait

Co-Founder Non-Executive Director

Over 15 years of entrepreneurial, corporate finance and strategy experience working in Israel, Europe and LATAM markets. Leading strategy and M&A at IMC (NASDAQ: IMCC, CSE: IMCC) with total activity of over US$180m. Formerly director of Israeli operations at MSW Capital, a Rio-based Brazilian M&A and advisory boutique firm leading business development and investment transactions between Israel and Brazil. Roy has served as senior consultant at Israel KPMG corporate finance. Mr Kait is a pilot (res.) in the Israeli air force.

Advisory Board

Dr Anne Katrin Schlag


A Chartered Psychologist and Head of Research at Drug Science (the leading independent scientific body on drugs in the UK).


Leads the research for the Drug Science Medical Cannabis and Psychedelics Working Group.,including the improvement of patient access, with expertise across science and policy making, risk perception, risk management and risk communication.


Honorary Fellowships at Imperial College London and King’s College London.

17 Hanover Square, London W1S 1BN
info@psych.capital +442038387621